253 related articles for article (PubMed ID: 19461175)
1. [Palliative chemotherapy for metastatic breast cancer with capecitabine].
Inaba T; Kashiwaba M; Takeda Y; Komatsu H; Tomisawa Y; Takiyama I; Wakabayashi G
Gan To Kagaku Ryoho; 2009 May; 36(5):769-72. PubMed ID: 19461175
[TBL] [Abstract][Full Text] [Related]
2. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S
Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713
[TBL] [Abstract][Full Text] [Related]
3. Contemporary issues and the potential uses of capecitabine in metastatic breast cancer.
Barrett-Lee P; Bidard FC; Pierga JY
Cancer Treat Rev; 2009 Nov; 35(7):582-9. PubMed ID: 19632050
[TBL] [Abstract][Full Text] [Related]
4. A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
Lortholary A; Hardy-Bessard AC; Bachelot T; de Rauglaudre G; Alexandre J; Bourgeois H; Jaubert D; Paraiso D; Largillier R
Breast Cancer Res Treat; 2012 Jan; 131(1):127-35. PubMed ID: 21947680
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
6. Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study.
Tanaka M; Takamatsu Y; Anan K; Ohno S; Nishimura R; Yamamoto Y; Masuda N; Mitsuyama S; Tamura K;
Anticancer Drugs; 2010 Apr; 21(4):453-8. PubMed ID: 20075712
[TBL] [Abstract][Full Text] [Related]
7. Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.
Miles D; Zielinski C; Martin M; Vrdoljak E; Robert N
Eur J Cancer; 2012 Mar; 48(4):482-91. PubMed ID: 22257791
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Aprile G; Mazzer M; Moroso S; Puglisi F
Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
[TBL] [Abstract][Full Text] [Related]
9. Mitomycin C plus capecitabine (mixe) in anthracycline- and taxane-pretreated metastatic breast cancer. A multicenter phase II study.
Maisano R; Caristi N; Mare M; Raffaele M; Iorfida M; Mafodda A; Zavettieri M; Nardi M
Anticancer Res; 2007; 27(4C):2871-5. PubMed ID: 17695463
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
11. [More effective positioning of capecitabine for advanced and metastatic breast cancer].
Tsuyuki S; Kawaguchisakita N; Tsubota Y; Ukikusa M; Kohno Y
Gan To Kagaku Ryoho; 2010 Apr; 37(4):649-53. PubMed ID: 20414020
[TBL] [Abstract][Full Text] [Related]
12. [A phase I study of combination therapy with capecitabine and paclitaxel for patients with inoperable breast cancer or recurrent breast cancer].
Horiguchi J; Koibuchi Y; Rokutanda N; Nagaoka R; Kikuchi M; Sato A; Odawara H; Ishikawa Y; Tokiniwa H; Iino Y; Takeyoshi I
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1877-81. PubMed ID: 19011335
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
14. Dose-finding study of capecitabine in combination with weekly paclitaxel for patients with anthracycline-pretreated metastatic breast cancer.
Susnjar S; Bosnjak S; Radulovic S; Stevanovic J; Gajic-Dobrosavljevic M; Kreacic M
J BUON; 2007; 12(2):189-96. PubMed ID: 17600871
[TBL] [Abstract][Full Text] [Related]
15. Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials.
Blum JL; Kohles J; McKenna E; Scotto N; Hu S; Odom D; Kaye JA; Glück S
Breast Cancer Res Treat; 2011 Jan; 125(2):431-9. PubMed ID: 21042933
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
Michalaki V; Fotiou S; Gennatas S; Gennatas C
Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib: new drug. For some women with metastatic breast cancer.
Prescrire Int; 2009 Feb; 18(99):9. PubMed ID: 19382400
[No Abstract] [Full Text] [Related]
19. Could the hand-foot syndrome after capecitabine treatment be associated with better outcome in metastatic breast cancer patients?
Kurt M; Aksoy S; Guler N
Acta Oncol; 2006; 45(5):625-6. PubMed ID: 16864181
[No Abstract] [Full Text] [Related]
20. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
